Filter

Refine by collections

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 199 items for :

  • "molecular markers" x
  • Refine by access: All content x
Clear All
Judith A Gilbert Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Judith A Gilbert in
Google Scholar
PubMed Close
,
Laura J Adhikari Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Laura J Adhikari in
Google Scholar
PubMed Close
,
Ricardo V Lloyd Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Ricardo V Lloyd in
Google Scholar
PubMed Close
,
Joseph Rubin Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Joseph Rubin in
Google Scholar
PubMed Close
,
Paul Haluska Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Paul Haluska in
Google Scholar
PubMed Close
,
Joan M Carboni Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Joan M Carboni in
Google Scholar
PubMed Close
,
Marco M Gottardis Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Marco M Gottardis in
Google Scholar
PubMed Close
, and
Matthew M Ames Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Matthew M Ames in
Google Scholar
PubMed Close

immunohistochemical staining (intensity score of 3) for the ten molecular markers studied. Hsp90, TGFBR1, IGF1R, and SSTR5 (the strongest staining biomarkers for the largest number of NETs) were expressed in all tumors from 20 cases in which primary and metastatic

Article Type:
Research Article
DOI:
https://doi.org/10.1677/ERC-09-0318
Volume/Issue:
Volume 17: Issue 3
Free access
Dermot O'Toole Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland

Search for other papers by Dermot O'Toole in
Google Scholar
PubMed Close
,
Anne Couvelard Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland

Search for other papers by Anne Couvelard in
Google Scholar
PubMed Close
,
Vinciane Rebours Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland

Search for other papers by Vinciane Rebours in
Google Scholar
PubMed Close
,
Magali Zappa Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland

Search for other papers by Magali Zappa in
Google Scholar
PubMed Close
,
Olivia Hentic Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland

Search for other papers by Olivia Hentic in
Google Scholar
PubMed Close
,
Pascal Hammel Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland

Search for other papers by Pascal Hammel in
Google Scholar
PubMed Close
,
Philippe Levy Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland

Search for other papers by Philippe Levy in
Google Scholar
PubMed Close
,
Pierre Bedossa Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland

Search for other papers by Pierre Bedossa in
Google Scholar
PubMed Close
,
Eric Raymond Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland

Search for other papers by Eric Raymond in
Google Scholar
PubMed Close
, and
Philippe Ruszniewski Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland

Search for other papers by Philippe Ruszniewski in
Google Scholar
PubMed Close

aggressive GEP-NETs but their influence on therapy is unknown. Several putative molecular markers predicting either sensitivity or resistance to oncological therapeutics have been proposed. The multidrug resistance protein and other ABC transporters have well

Article Type:
Research Article
DOI:
https://doi.org/10.1677/ERC-09-0204
Volume/Issue:
Volume 17: Issue 4
Free access
Andreas Venizelos K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway
Department of Oncology, Haukeland University Hospital, Bergen, Norway

Search for other papers by Andreas Venizelos in
Google Scholar
PubMed Close
,
Hege Elvebakken Department of Oncology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Ålesund, Norway
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

Search for other papers by Hege Elvebakken in
Google Scholar
PubMed Close
,
Aurel Perren Institute of Pathology, University of Bern, Bern, Switzerland

Search for other papers by Aurel Perren in
Google Scholar
PubMed Close
,
Oleksii Nikolaienko K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway
Department of Oncology, Haukeland University Hospital, Bergen, Norway

Search for other papers by Oleksii Nikolaienko in
Google Scholar
PubMed Close
,
Wei Deng K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway
Department of Oncology, Haukeland University Hospital, Bergen, Norway

Search for other papers by Wei Deng in
Google Scholar
PubMed Close
,
Inger Marie B Lothe Department of Pathology, Oslo University Hospital, Oslo, Norway

Search for other papers by Inger Marie B Lothe in
Google Scholar
PubMed Close
,
Anne Couvelard Department of Pathology, Université de Paris, Bichat Hospital, AP-HP, Paris, France

Search for other papers by Anne Couvelard in
Google Scholar
PubMed Close
,
Geir Olav Hjortland Department of Oncology, Oslo University Hospital, Oslo, Norway

Search for other papers by Geir Olav Hjortland in
Google Scholar
PubMed Close
,
Anna Sundlöv Departmentt of Oncology, Skåne University Hospital, Lund, Sweden
Department of Medical Radiation Physics, Lund University, Lund, Sweden

Search for other papers by Anna Sundlöv in
Google Scholar
PubMed Close
,
Johanna Svensson Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden

Search for other papers by Johanna Svensson in
Google Scholar
PubMed Close
,
Harrish Garresori Department of Oncology, Stavanger University Hospital, Stavanger, Norway

Search for other papers by Harrish Garresori in
Google Scholar
PubMed Close
,
Christian Kersten Department of Research, Hospital of Southern Norway, Kristiansand, Norway

Search for other papers by Christian Kersten in
Google Scholar
PubMed Close
,
Eva Hofsli Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
Department of Oncology, St.Olavs Hospital, Trondheim, Norway

Search for other papers by Eva Hofsli in
Google Scholar
PubMed Close
,
Sönke Detlefsen Department of Pathology, Odense University Hospital, Odense, Denmark
Department of Clinical Medicine, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

Search for other papers by Sönke Detlefsen in
Google Scholar
PubMed Close
,
Merete Krogh Department of Oncology, Odense University Hospital, Odense, Denmark

Search for other papers by Merete Krogh in
Google Scholar
PubMed Close
,
Halfdan Sorbye Department of Oncology, Haukeland University Hospital, Bergen, Norway
Department of Clinical Science, University of Bergen, Bergen, Norway

Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed Close
, and
Stian Knappskog K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway
Department of Oncology, Haukeland University Hospital, Bergen, Norway

Search for other papers by Stian Knappskog in
Google Scholar
PubMed Close

have associated microsatellite instability (MSI) with improved prognosis ( La Rosa et al. 2012 , Sahnane et al. 2015 ). However, molecular markers for classification, treatment selection and prognosis for HG GEP-NEN are generally lacking. Some

Article Type:
Research Article
Collections:
Top-cited articles of 2023
DOI:
https://doi.org/10.1530/ERC-21-0152
Volume/Issue:
Volume 29: Issue 1
Open access
Esra Karslioglu French Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Search for other papers by Esra Karslioglu French in
Google Scholar
PubMed Close
,
Alyaksandr V Nikitski Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Search for other papers by Alyaksandr V Nikitski in
Google Scholar
PubMed Close
,
Linwah Yip Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Search for other papers by Linwah Yip in
Google Scholar
PubMed Close
,
Marina N Nikiforova Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Search for other papers by Marina N Nikiforova in
Google Scholar
PubMed Close
,
Yuri E Nikiforov Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Search for other papers by Yuri E Nikiforov in
Google Scholar
PubMed Close
, and
Sally E Carty Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Search for other papers by Sally E Carty in
Google Scholar
PubMed Close

EIF1AX gene mutations are reported in both benign and malignant thyroid tumors, with unclear outcomes when detected preoperatively. The aim of this study was to determine the features and outcomes of thyroid nodules with various types of mutation identified in cytologic (fine-needle aspiration) samples on preoperative ThyroSeq testing and with surgical outcomes. In this single-institution retrospective study of 31 consecutive patients, 77% were female and nodule size ranged from 1.5 to 9.4 cm with widely varying cytologic and TI-RADS ultrasound categorizations. Among two main mutational hotspots, 55% were located in exon 2 and 45% at the intron 5/exon 6 splice site. On histology, 45% of -positive nodules were cancer/noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) including 19% encapsulated follicular variant papillary thyroid carcinoma, 10% follicular carcinoma, 10% anaplastic carcinoma (ATC), and 7% NIFTP. Almost half (48%) of patients had one or more coexisting mutations, most frequently RAS. The prevalence of cancer/NIFTP was 80% for mutation with coexisting molecular alteration vs 13% with an isolated mutation (P  = 0.0002). Cancer probability was associated with mutation type and was 64% for splice-site mutation and 29% for non-splice mutation (P = 0.075). All 3 nodules with EIF1AX+RAS+TERT+TP53 mutations were ATC. In summary, in this study, all nodules with an isolated non-splice mutation were benign, one-third of those with an isolated splice mutation were cancer, and most nodules with coexisting with RAS or other alterations were malignant. These findings suggest that clinical management decisions for patients with EIF1AX-mutant nodules should consider both the type of mutation and its co-occurrence with other genetic alterations.

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-22-0041
Volume/Issue:
Volume 29: Issue 8
Restricted access
Susan J Hsiao Division of Molecular and Genomic Pathology, Department of Pathology, University of Pittsburgh School of Medicine, 3477 Euler Way, Room 8031, Pittsburgh, Pennsylvania 15213, USA

Search for other papers by Susan J Hsiao in
Google Scholar
PubMed Close
and
Yuri E Nikiforov Division of Molecular and Genomic Pathology, Department of Pathology, University of Pittsburgh School of Medicine, 3477 Euler Way, Room 8031, Pittsburgh, Pennsylvania 15213, USA

Search for other papers by Yuri E Nikiforov in
Google Scholar
PubMed Close

need for molecular markers The diagnosis of thyroid cancer is typically obtained through ultrasound examination and fine-needle aspiration (FNA) biopsy of suspicious nodules. Cytological examination of cells collected by FNA biopsy is the most reliable

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-14-0166
Volume/Issue:
Volume 21: Issue 5
Free access
P J Barrett-Lee Cardiff Breast Unit, Velindre NHS Trust, Cardiff CF14 2 TL, UK

Search for other papers by P J Barrett-Lee in
Google Scholar
PubMed Close

other candidate markers for a way forward. Molecular markers for chemotherapy response At the present time, no single predictive biological marker has become established in routine practice in breast cancer to assess clinical

Article Type:
Research Article
DOI:
https://doi.org/10.1677/erc.1.01024
Volume/Issue:
Volume 12: Issue Supplement_1
Free access
Vincenzo Condello Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa, Pisa, Italy
Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Search for other papers by Vincenzo Condello in
Google Scholar
PubMed Close
,
Filomena Cetani Endocrine Unit, University Hospital of Pisa, Pisa, Italy

Search for other papers by Filomena Cetani in
Google Scholar
PubMed Close
,
Maria Denaro Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa, Pisa, Italy

Search for other papers by Maria Denaro in
Google Scholar
PubMed Close
,
Liborio Torregrossa Division of Surgical Pathology, University Hospital of Pisa, Pisa, Italy

Search for other papers by Liborio Torregrossa in
Google Scholar
PubMed Close
,
Elena Pardi Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Search for other papers by Elena Pardi in
Google Scholar
PubMed Close
,
Paolo Piaggi Department of Information Engineering, University of Pisa, Pisa, Italy

Search for other papers by Paolo Piaggi in
Google Scholar
PubMed Close
,
Simona Borsari Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Search for other papers by Simona Borsari in
Google Scholar
PubMed Close
,
Anello Marcello Poma Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa, Pisa, Italy

Search for other papers by Anello Marcello Poma in
Google Scholar
PubMed Close
,
Lucia Anna Muscarella Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, Laboratory of Oncology, San Giovanni Rotondo (FG), Italy

Search for other papers by Lucia Anna Muscarella in
Google Scholar
PubMed Close
,
Paolo Graziano Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, Unit of Pathology, San Giovanni Rotondo (FG), Italy

Search for other papers by Paolo Graziano in
Google Scholar
PubMed Close
,
Maria Grazia Chiofalo Fondazione IRCCS G. Pascale, Thyroid and Parathyroid Surgery Unit, Istituto Nazionale Tumori, Naples, Italy

Search for other papers by Maria Grazia Chiofalo in
Google Scholar
PubMed Close
,
Andrea Repaci Endocrinology Unit, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

Search for other papers by Andrea Repaci in
Google Scholar
PubMed Close
,
Giovanni Tallini Department of Medicine, Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna, Italy

Search for other papers by Giovanni Tallini in
Google Scholar
PubMed Close
,
Francesco Boi Department of Medical Sciences and Public Health, Endocrinology Unit, University of Cagliari, Cagliari, Italy

Search for other papers by Francesco Boi in
Google Scholar
PubMed Close
,
Gabriele Materazzi Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa, Pisa, Italy

Search for other papers by Gabriele Materazzi in
Google Scholar
PubMed Close
,
Fulvio Basolo Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa, Pisa, Italy

Search for other papers by Fulvio Basolo in
Google Scholar
PubMed Close
, and
Claudio Marcocci Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Search for other papers by Claudio Marcocci in
Google Scholar
PubMed Close

( Riker et al. 2008 , Ganepola et al. 2010 , Condello et al. 2019 ). In order to identify molecular markers to apply in the differential diagnosis of parathyroid tumors, with a particular focus on PC progression, we investigated a wide panel of

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-20-0450
Volume/Issue:
Volume 28: Issue 2
Restricted access
Ruth Foley Department of Haematology and Oncology, Institute of Molecular Medicine, St James’ Hospital, James’ St, Dublin 8, Ireland

Search for other papers by Ruth Foley in
Google Scholar
PubMed Close
,
Donal Hollywood Department of Haematology and Oncology, Institute of Molecular Medicine, St James’ Hospital, James’ St, Dublin 8, Ireland

Search for other papers by Donal Hollywood in
Google Scholar
PubMed Close
, and
Mark Lawler Department of Haematology and Oncology, Institute of Molecular Medicine, St James’ Hospital, James’ St, Dublin 8, Ireland

Search for other papers by Mark Lawler in
Google Scholar
PubMed Close

mechanisms, including cross-activation by agents such as IGF-I ( Culig et al. 1994 ). Potential new molecular markers such as hepsin ( Rhodes et al. 2002 ) have been identified. These and other identified and novel genes implicated in the disease

Article Type:
Research Article
DOI:
https://doi.org/10.1677/erc.1.00699
Volume/Issue:
Volume 11: Issue 3
Free access
Bruno Ragazzon Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France
Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France

Search for other papers by Bruno Ragazzon in
Google Scholar
PubMed Close
,
Guillaume Assié Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France
Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France
Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France

Search for other papers by Guillaume Assié in
Google Scholar
PubMed Close
, and
Jérôme Bertherat Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France
Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France
Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France

Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed Close

et al . 1993 , Rainier et al . 1993 , Gicquel et al . 1997 ). Interestingly, it has been previously demonstrated that IGF2 expression could be used as a molecular marker for the diagnosis of ACC ( Gicquel et al . 2001 ). The IGF signaling pathway

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-10-0220
Volume/Issue:
Volume 18: Issue 2
Free access
C J Fabian
Search for other papers by C J Fabian in
Google Scholar
PubMed Close
,
B F Kimler
Search for other papers by B F Kimler in
Google Scholar
PubMed Close
,
M S Mayo
Search for other papers by M S Mayo in
Google Scholar
PubMed Close
, and
S A Khan
Search for other papers by S A Khan in
Google Scholar
PubMed Close

and/or RPFNA, there is a great deal of interest in supplementing morphologic interpretations with molecular markers ( Fabian et al. 2002 , Ljung et al. 2004 , Gornstein et al. 2004 , Sneige 2004 ). Simple assessment of ploidy has been

Article Type:
Review Article
DOI:
https://doi.org/10.1677/erc.1.01000
Volume/Issue:
Volume 12: Issue 2
Free access